Know Cancer

forgot password

A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Phase 2
18 Years
Open (Enrolling)
Uveal Melanoma

Thank you

Trial Information

A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed metastatic uveal

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as >
or = to 20 mm with conventional techniques or as > or = to 10 mm with spiral CT scan.

- Patients may have had any number of prior therapies, but cannot have previously been
treated with a somatostatin analogue or an mTOR inhibitor. At least 3 weeks must have
elapsed since the last dose of systemic therapy. At least 6 weeks must have elapsed
if the last regimen included BCNU or mitomycin C. At least 3 months must have elapsed
if the last regimen included an anti-CTLA4 antibody. If the last regimen included an
anti-CTLA4 antibody, radiographic disease progression since this therapy must be

- Age > or = to 18 years. Because no dosing or adverse event data are currently
available on the use of RAD001 and SOM230 in patients <18 years of age, children are
excluded from this study but will be eligible for future pediatric trials, if

- Life expectancy of greater than 3 months.

- ECOG performance status 0 or 1.

- Patients must have normal organ and marrow function as defined below:

- leukocytes > or = to 3,000/mcL

- absolute neutrophil count > or = to 1,500/mcL

- platelets > or = to 100,000/mcL

- hemoglobin > or = to 9.0 g/dL not requiring transfusions within the past 2 weeks

- total bilirubin < 1.5 X institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal

- Creatinine ≤ 1.5 X institutional upper limit of normal or creatinine clearance less
than 60 ml/min

- Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5
x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can
only be included after initiation of appropriate lipid lowering medication.

- INR ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of
warfarin or on a stable dose of LMW heparin for >2 weeks at time of study

- Women of childbearing potential must have a negative serum pregnancy test within 14
days of the administration of the first study treatment. Women must not be lactating.
Both men and women of childbearing potential must be advised of the importance of
using effective birth control measures during the course of the study. Oral,
implantable, or injectable contraceptives may be affected by cytochrome P450
interactions, and are therefore not considered effective for this study.

- Ability to understand and the willingness to sign a written informed consent

- Evidence of disease progression, as determined by the investigator.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to
require glucocorticoids for brain or leptomeningeal metastases. Treated brain
metastases must have been stable for at least 2 months.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to RAD001 or SOM230.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or bleeding, severely impaired lung function, or psychiatric illness/social
situations that would limit compliance with study requirements.

- Pregnant women are excluded from this study because RAD001 and SOM230 are agents with
the potential for teratogenic or abortifacient effects. Because there is an unknown
but potential risk for adverse events in nursing infants, breast-feeding should be

- Patients with the presence of active or suspected acute or chronic uncontrolled
infection or with a history of immunocompromise, including a positive HIV test result
(ELISA and Western blot). The safety of a potentially immunosuppressive drug like
everolimus is not proven in patients with HIV. HBV DNA and HCV RNA PCR testing are
required at screening for all patients with a positive medical history based on risk
factors and/or confirmation of prior HBV/HCV infection (see Section 8.0 and hepatitis
B/C risk factor screening form.

- Baseline QTc > 450 ms.

- Patients with risk factors for torsades de pointes, including uncorrected
hypokalemia, uncorrected hypomagnesemia, family history of long QT syndrome,
clinically significant/symptomatic bradycardia, high-grade AV block, autonomic
neuropathy (including that caused by diabetes or Parkinson's disease, uncontrolled
hypothyroidism, cirrhosis, or the use of concomitant medications known to prolong the
QT interval.

- Patients with a history of syncope, family history of idiopathic sudden death, a
history of sustained or clinically significant cardiac arrhythmias, symptomatic
congestive heart failure (NYHA Class III or IV), unstable angina pectoris, sustained
ventricular tachycardia, ventricular fibrillation, advanced heart block, or a history
of acute myocardial infarction within the six months preceding enrollment .

- No concomitant anti-cancer chemotherapy or other systemic drugs. Palliative radiation
therapy will be allowed as long as the patient meets all other eligibility criteria.

- Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory
bowel disease), or significant bowel resection that would preclude adequate

- Chronic treatment with systemic steroids or another immunosuppressive agent.

- Patients should not receive immunization with attenuated live vaccines during study
period or within 1 week of study entry. Close contact with those who have received
attenuated live vaccines should be avoided during treatment with RAD001. Examples of
live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG,
yellow fever, varicella and TY21a typhoid vaccines.

- Patients with prior or concurrent malignancy except for the following: adequately
treated basal cell or squamous cell skin cancer, or other adequately treated in situ
cancer, or any other cancer from which the patient has been disease free for five

- Patients with a fasting plasma glucose > 1.5 ULN. Note: At the principle
investigator's discretion, non-eligible patients can be re-screened after adequate
medical therapy has been instituted.

- Patients with symptomatic cholelithiasis.

- Patients who have a history of alcohol or drug abuse in the 6 month period prior to
receiving treatment with pasireotide or RAD001.

- History of liver disease, such as cirrhosis or chronic active hepatitis B and C.

- Presence of Hepatitis B surface antigen (HbsAg).

- Presence of Hepatitis C antibody test (anti-HCV).

- History of, or current alcohol misuse/abuse within the past 12 months.

- Known gallbladder or bile duct disease, acute or chronic pancreatitis.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the clinical benefit rate as defined as complete response (CR)

Outcome Description:

For patients with metastatic uveal melanoma treated with RAD001 and pasireotide LAR.

Outcome Time Frame:

at 16 weeks

Safety Issue:


Principal Investigator

Richard Carvajal, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

November 2010

Completion Date:

November 2014

Related Keywords:

  • Uveal Melanoma
  • eye
  • 10-123
  • Melanoma
  • Uveal Neoplasms



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021